<DOC>
	<DOCNO>NCT00611325</DOCNO>
	<brief_summary>Primary Objective To estimate 6-month progression free survival probability patient recurrent glioblastoma multiforme treat bortezomib plus Avastin . This efficacy assessment make separately among patient enzyme-inducing anti-epileptic drug non enzyme-inducing anti-epileptic drug . Secondary Objectives To evaluate safety &amp; tolerability bortezomib plus Avastin among patient recurrent malignant glioma . To evaluate radiographic response , progression free survival &amp; overall survival patient recurrent malignant glioma treat bortezomib plus Avastin</brief_summary>
	<brief_title>Phase II Avastin + Bortezomib Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>This open-label , 2-arm Phase II study assess safety &amp; efficacy bortezomib combination Avastin patient recurrent glioblastoma multiforme ( gbm ) . 56 total patient recurrent WHO grade IV malignant glioma enrol study . Avastin administer intravenously dose 15 mg/kg every 3 week . Bortezomib administer day 1 , 4 , 8 , 11 , 22 , 25 , 29 , &amp; 32 42-day cycle . The dose bortezomib 1.7 mg/m2 non-EIAED patient &amp; 2.5 mg/m2 EIAED patient . Treatment continue either evidence progressive disease , unacceptable toxicity , non-compliance study follow-up / withdrawal consent . Brain MRIs obtain every cycle . Bortezomib administration associate mild toxicity patient , fatigue , diarrhea &amp; nausea , constipation &amp; peripheral neuropathy . Less common , bortezomib administration lead significant hematologic toxicity &amp; peripheral neuropathy . Most significant toxicity associate Avastin recently complete phase II clinical trial Duke thrombotic complication &amp; grade 2 proteinuria . `` Unacceptable '' toxicity rate 15 percent less consider desirable , rate 40 percent great consider undesirable . The statistical hypothesis need test differentiate 15 % &amp; 40 % rate unacceptable toxicity .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients histologically confirm diagnosis recurrent/progressive WHO grade IV malignant glioma ( MG ) Age &gt; 18 yr No prior treatment bortezomib , &amp; Avastin last 3 month , allow progress Avastin regimen . No history &gt; equal grade 2 CNS hemorrhage grade 3 high toxicity Avastin At least 6 week surgical resection , 4 week end radiotherapy &amp; enrollment study Karnofsky Performance Status ( KPS ) &gt; equal 70 % Hemoglobin ( Hgb ) &gt; = 9 g/deciliter ( dL ) , absolute neutrophil count ( ANC ) &gt; = 1,500 cells/microliter , platelet &gt; = 125,000 cells/microliter ; Serum creatinine &lt; 1.5 mg/dL , serum glutamic oxalocetic transaminase ( SGOT ) &amp; bilirubin &lt; 1.5 x upper limit normal Signed inform consent approve IRB ; If sexually active , patient must agree take contraceptive measure duration treatment May 3 biological therapy ( tyrosine kinase inhibitor , topoisomerase I II inhibitor , rapamycin ) Gr 2 great peripheral neuropathy time study enrollment No prior taxanes , predisposes sensory neuropathy Comedication may interfere study result , e.g . immunosuppressive agent corticosteroid Greater 3 prior recurrence Evidence CNS hemorrhage baseline MRI CT scan ( except grade 1 hemorrhage stable least 3 month ) History thrombotic hemorrhagic stroke myocardial infarction within 6 month Requires therapeutic anticoagulation At least 4 week Day 0 prior monthly chemotherapy ( least 6 week nitrosourea ) . At least 1 week last dose daily chemotherapy ( metronomic temozolomide , cytoxan ) target therapy administer daily ( gleevec , tarceva ) Pregnancy breast feeding Uncontrolled intercurrent illness include , limited , ongoing active infection require IV antibiotic &amp; psychiatric illness/social situation would limit compliance study requirement , disorder associate significant immunocompromised state Patients another primary malignancy require treatment within past year . AvastinSpecific Concerns : Any prior history hypertensive crisis hypertensive encephalopathy Systolic blood pressure ( BP ) &gt; 150 mmHg diastolic BP &gt; 100 mmHg Unstable angina New York Heart Association Gr II &gt; congestive heart failure History myocardial infarction within 6 month History stroke within 6 month Clinically significant peripheral vascular disease Evidence bleeding diathesis , coagulopathy document elevated prothrombin time ( PT ) , partial thromboplastin time ( PTT ) /bleeding time Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior Day 0 Urine protein : creatinine ratio &gt; = 1.0 screen History abdominal fistula , GI perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Known hypersensitivity component Avastin Inability comply study and/or followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Recurrent malignant glioma</keyword>
	<keyword>GBM</keyword>
	<keyword>Recurrent GBM</keyword>
	<keyword>Malignant glioma</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
</DOC>